Publicaties onderzoeken Cannabidiol (CBD)

Hier vindt u verschillende publicaties over CBD, gesorteerd naar ziektebeeld. Door de URL te kopiëren in uw browser komt u op de website van het National Center for Biotechnology Information.

ADD / ADHD
Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and
hyperactivity in Sprague-Dawley rats.
http://www.ncbi.nlm.nih.gov/pubmed/22495620

Addiction
Cannabidiol reduces cigarette consumption in tobacco smokers
http://www.ncbi.nlm.nih.gov/pubmed/23685330

AIDS
Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-
associated herpesvirus-infected endothelium
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527984/

ALS
Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications,
and a call for clinical trials.
http://www.ncbi.nlm.nih.gov/pubmed/20439484

Alzheimer’s
Cannabidiol: a promising drug for neurodegenerative disorders?
http://www.ncbi.nlm.nih.gov/pubmed/19228180

Anorexia
Leptin, ghrelin, and endocannabinoids: potential therapeutic targets in anorexia
nervosa.
http://www.ncbi.nlm.nih.gov/pubmed/18926548

Antibiotic resistance
Antibacterial activity of delta9-tetrahydrocannabinol and cannabidiol.
http://www.ncbi.nlm.nih.gov/pubmed/1085130

Anxiety
Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
http://www.ncbi.nlm.nih.gov/pubmed/22729452

Atherosclerosis
The role of the endocannabinoid system in atherosclerosis.
http://www.ncbi.nlm.nih.gov/pubmed/18426500

Arthritis
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic
therapeutic in murine collagen-induced arthritis.
http://www.ncbi.nlm.nih.gov/pubmed/10920191

Asthma
The role of eannabinoids in inflammatory modulation of allergie respiratory
disorders, inflammatory pain and ischemie stroke.
htlp://www.ncbi.nlm.nih.gov/pubmed/22420307

Autism
Targeting the endoeannabinoid system in the treatment of fragile X syndrome.
http://www.ncbi.nlm.nih.gov/pubmed/23542787

Bipolar
Cannabinoids in bipolar affeetive disorder: a review and discussion of their
therapeutie potential.
http://www.ncbi.nlm.nih.gov/pubmed/15888515

Cancer
Cannabidiol as potential anticancer drug.
http://www.ncbi.nlm.nih.gov/pubmed/22506672

Colitis / Crohn’s
Cannabidiol in inflammatory bowel diseases: a brief overview.
http://www.ncbi.nlm.nih.gov/pubmed/22815234

Depression
Antidepressant-like effects of eannabidiol in miee: possible involvement of 5-HT1 A
receptors.
http://www.ncbi.nlm.nih.gov/pubmed/20002102

Diabetes
Cannabidiol arrests onset of autoimmune diabetes in NOO mice.
http://www.ncbi.nlm.nih.gov/pubmed/17714746

Endocrine disorders
Endocannabinoid system participates in neuroendocrine contral of homeostasis.
http://www.ncbi.nlm.nih.gov/pubmed/20134190

Epilepsy / seizure
Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and
partial seizures.
http://www.ncbi.nlm.nih.gov/pubmed/22520455

Fibromyalgia
Clinical endocannabinoid deficiency (CECD): can this concept explain therapeut ic
benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other
treatment-resistant conditions?
http://www.ncbi.nlm.nih.gov/pubmed/18404144

Glaucoma
Effect of sublingual application of cannabinoids on intraocular pressure: a pilot
study.
http://www.ncbi.nlm.nih.gov/pubmed/16988594

Heart disease
Is the cardiovascular system a therapeutic target for cannabidiol?
http://www.ncbi.nlm.nih.gov/pubmed/22670794

Huntington’s
Cannabinoids: novel medicines tor the treatment of Huntington’s disease.
http://www.ncbi.nlm.nih.gov/pubmed/22280340

Inflammation
Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.
http://www.ncbi.nlm.nih.gov/pubmed/21238581

Irritable bowel Syndrome
Cannabidiol in inflammatory bowel diseases: a brief overview.
http://www.ncbi.nlm.nih.gov/pubmed/22815234

Kidney disease
Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/
nitrosative stress, inflammation, and cell death.
http://www.ncbi.nlm.nih.gov/pubmed/19074681

Liver disease
The endocannabinoid system and liver diseases.
http://www.ncbi.nlm.nih.gov/pubmed/18426499

Metabolic syndrome
The potential use of cannabidiol in the therapy of metabolic syndrome
http://www.ncbi.nlm.nih.gov/pubmed/22430005

Migraine
Effects of anandamide in migraine: data from an animal model.
http://www.ncbi.nlm.nih.gov/pubmed/21331757

Mood disorders
The endocannabinoid system and the treatment of mood and anxiety disorders.
http://www.ncbi.nlm.nih.gov/pubmed/19839936

Motion sickness
Motion sickness, stress and the endocannabinoid system.
http://www.ncbi.nlm.nih.gov/pubmed/20505775

Multiple sclerosis
Sativex for the management of multiple sclerosis symptoms.
http://www.ncbi.nlm.nih.gov/pubmed/16317825

Nausea
Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and
nausea-like behaviour via indirect agonism of 5-HT(1 A) somatodendritic
autoreceptors in the dorsal rap he nucleus.
http://www.ncbi.nlm.nih.gov/pubmed/21827451

Neurodegeneration
Cannabidiol: a promising drug tor neurodegenerative disorders?
http://www.ncbi.nlm.nih.gov/pubmed/19228180

Neuropathie pain
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-
related pain.
http://www.ncbi.nlm.nih.gov/pubmed/17257464

Obesity
Cannabinol and cannabidiol exert opposing effects on rat feeding patterns.
http://www.ncbi.nlm.nih.gov/pubmed/22543671

OCD
Plasma and brain pharmacokinetic profile of cannabidiol (CSD), cannabidivarine
(CBDV), A9-tetrahydrocannabivarin (THCV) and cannabigerol (CSG) in rats and mice
following oral and intraperitoneal administration and CSD action on obsessive-
compulsive behaviour.
http://www.ncbi.nlm.nih.gov/pubmed/21796370

Osteoporosis
Cannabinoid receptors as target for treatment of osteoporosis: a tale of two
therapies.
http://www.ncbi.nlm.nih.gov/pubmed/21358974

Parkinson’s
Cannabidiol for the treatment of psychosis in Parkinson’s disease.
http://www.ncbi.nlm.nih.gov/pubmed/18801821

Mad Cow disease
Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons
against prion toxicity.
http://www.ncbi.nlm.nih.gov/pubmed/17804615

Rheumatism
Cannabidiol as an emergent therapeutic strategy for lessening the impact of
inflammation on oxidative stress.
http://www.ncbi.nlm.nih.gov/pubmed/21238581

Schizophrenia
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
http://www.ncbLnlm.nih.gov/pubmed/16612464

Siekle eell anemia
Pain-related behaviors and neurochemical alterations in mice expressing sickie
hemoglobin: modulation by cannabinoids.
http://www.ncbi.nlm.nih.gov/pubmed/20304807

Skin conditions
The endocannabinoid system of the skin in health and disease: novel perspectives
and therapeutic opportunities.
http://www.ncbi.nlm.nih.gov/pubmed/19608284

Sleep disorders
The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent.
http://www.ncbi.nlm.nih.gov/pubmed/19045957

Spinal cord injury
Cannabidiol-treated rats exhibited higher motor score after cryogenic spinel cord
injury.
http://www.ncbi.nlm.nih.gov/pubmed/21915768

Stress
The anxiolytic effect of cannabidiol on chronically stressed mice depends on
hippocampal neurogenesis: involvement of the endocannabinoid system.
http://www.ncbi.nlm.nih.gov/pubmed/23298518

Stroke / TBI
Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial
ischemie reperfusion injury.
http://www.ncbi.nlm.nih.gov/pubmed/17890433